|Application ||WB, E|
|Other Accession||Q9R1J8, Q3V1T4|
|Calculated MW||83394 Da|
|Other Names||Prolyl 3-hydroxylase 1, Growth suppressor 1, Leucine- and proline-enriched proteoglycan 1, Leprecan-1, LEPRE1, GROS1, P3H1|
|Target/Specificity||This LEPRE1 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 499-533 amino acids from the Central region of human LEPRE1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||LEPRE1 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Basement membrane-associated chondroitin sulfate proteoglycan (CSPG). Has prolyl 3-hydroxylase activity catalyzing the post-translational formation of 3-hydroxyproline in -Xaa-Pro- Gly- sequences in collagens, especially types IV and V. May be involved in the secretory pathway of cells. Has growth suppressive activity in fibroblasts.|
|Cellular Location||Isoform 1: Endoplasmic reticulum.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Basement membrane-associated chondroitin sulfate proteoglycan (CSPG). Has prolyl 3-hydroxylase activity catalyzing the post-translational formation of 3-hydroxyproline in -Xaa-Pro- Gly- sequences in collagens, especially types IV and V. May be involved in the secretory pathway of cells. Has growth suppressive activity in fibroblasts.
Kaul S.C.,et al.Oncogene 19:3576-3583(2000).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Otsuki T.,et al.DNA Res. 12:117-126(2005).
Kalnine N.,et al.Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
Cabral W.A.,et al.Nat. Genet. 39:359-365(2007).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.